| Dataset | DGIdb Drug Targets 2026 |
| Category | physical interactions |
| Type | drug |
| Description | A sulfonamide obtained by formal condensation of the sulfonic acid group of 4-[(3-methoxy-4-methylbenzoyl)amino]benzenesulfonic acid with the primary aromatic amino group of N-(3,5-dimethoxyphenyl)quinoxaline-2,3-diamine. A dual PI3K/mTOR inhibitor used in cancer treatment. (Chemical Entities of Biological Interest Ontology, CHEBI_71958) |
| External Link | https://dgidb.org/results?searchType=drug&searchTerms=XL765 |
| Similar Terms | |
| Downloads & Tools |
4 interacting proteins for the XL765 drug from theDGIdb Drug Targets 2026 dataset.
| Symbol | Name | Standardized Value |
|---|---|---|
| MTOR | mechanistic target of rapamycin (serine/threonine kinase) | 0.149525 |
| PIK3CD | phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta | 0.106718 |
| PIK3CA | phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha | 0.093851 |
| PIK3CG | phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma | 0.0711451 |
